Objective: To investigate the clinical diagnosis, treatment and prognosis of melanoma adrenal metastasis.
Methods: A total of 48 cases of malignant melanoma from 1985 to 2007 were reviewed. And three cases of melanoma adrenal metastasis were analyzed. There were 2 males and 1 female with an age of 57, 70 and 83 years old respectively. Two cases had a history of cutaneous melanoma and another one suffered previously from anal melanoma. The disease-free interval to adrenal metastasis were 25, 37, 33 months respectively. Two presented with flank or abdominal discomfort and another one had adrenal metastasis on routine examination. The maximal diameters of metastasis were 5, 8 and 12 cm respectively. The CT value of adrenal metastasis had a range of 9 - 45 Hu in plain scan. And the maximal post-contrast value was 107.5 Hu.
Results: One patient with concurrent lymph node metastasis received non-operative therapy with interleukin-2. The other two cases underwent complete resection of melanoma metastasis. One received adrenalectomy via retroperitoneal laparoscopic approach while another patient with tumor thrombus in inferior vena cava underwent right adrenalectomy and extraction of tumor thrombus out of inferior vena cava in traditional open surgery. When contralateral adrenal metastasis of melanoma was found 6 months later, left adrenalectomy laparoscopically was performed. The patient who was managed non-operatively died of cachexia 6 months later. Two operated patients did not accept adjuvant therapy. One had multiple metastasis in 16 months and died at 21 months. Another was alive without recurrence or new metastasis at 30 months.
Conclusion: Melanoma metastasis to adrenal gland is rare and it generally has a poor prognosis. Patients with adrenal metastases from melanoma, either isolated or with a limited number of additional metastases, may achieve a survival benefit from surgical resection if all visible lesions are removed.
Download full-text PDF |
Source |
---|
Clin Genitourin Cancer
December 2024
The Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI, USA; The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Int J Colorectal Dis
January 2025
General Surgery, Cannizzaro Hospital, Catania, Italy.
In this article, we aim to demonstrate that thyroid carcinoma can metastasize to the small bowel. This case report involves a 66-year-old woman who underwent total thyroidectomy surgery in 2019, with histopathology revealing a 3A undifferentiated thyroid cancer. She presented with symptoms of bowel obstruction, including abdominal pain, nausea, and vomiting.
View Article and Find Full Text PDFProstate cancer frequently metastasizes to regional lymph nodes and bones, but metastasis to the adrenal glands remains rare, particularly in isolation. This case report presents an unusual instance of bilateral adrenal metastasis in a patient with castration-resistant prostate cancer. This case emphasizes the clinical relevance of adrenal metastasis in castration-resistant prostate cancer, highlighting the potential role of aggressive treatment strategies such as metastasectomy in isolated adrenal involvement, aiming to contribute to the limited literature on this rare metastatic pattern.
View Article and Find Full Text PDFHeliyon
January 2025
Laboratory of General, Molecular and Population Genetics, Endocrinology Research Center, Moscow, 117292, Russia.
The molecular mechanisms underlying adrenal and thyroid neuroendocrine tumors, including their tumorigenesis, progression, and metastasis, involve unique pathways regulating cell cycle progression. To better understand these mechanisms and pathways, extensive in-depth research on cell cycle-related genes is necessary. This review aims to describe and interpret current single-cell RNA sequencing studies on neuroblastoma, medullary thyroid cancer, and pheochromocytoma tumors.
View Article and Find Full Text PDFTransl Lung Cancer Res
December 2024
Department of Medical Oncology, Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, Paris, France.
Background: Oligoprogression (OP) is common in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs). This study aims to assess the benefit and the safety profile of ablative radiotherapy (RT) for OP in mNSCLC treated with pembrolizumab in first-line setting.
Methods: We retrospectively analyzed records of all consecutive mNSCLC patients who underwent treatment with pembrolizumab (+/- chemotherapy) in first-line setting and developed an OP treated with ablative RT while continuing pembrolizumab, in a French Hospital from 2019 to 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!